A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice

Kiyotoshi Kaneko, Haydn L. Ball, Holger Wille, Hong Zhang, Darlene Groth, Marilyn Torchia, Patrick Tremblay, Jiri Safar, Stanley B. Prusiner, Stephen J. DeArmond, Michael A. Baldwin, Fred E. Cohen

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

The molecular basis of the infectious, inherited and sporadic forms of prion diseases is best explained by a conformationally dimorphic protein that can exist in distinct normal and disease-causing isoforms. We identified a 55-residue peptide of a mutant prion protein that can be refolded into at least two distinct conformations. When inoculated intracerebrally into the appropriate transgenic mouse host, 20 of 20 mice receiving the β-form of this peptide developed signs of central nervous system dysfunction at ~360 days, with neurohistologic changes that are pathognomonic of Gerstmann-Straussler-Scheinker disease. By contrast, eight of eight mice receiving a non-β-form of the peptide failed to develop any neuropathologic changes more than 600 days after the peptide injections. We conclude that a chemically synthesized peptide refolded into the appropriate conformation can accelerate or possibly initiate prion disease. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)997-1007
Number of pages11
JournalJournal of Molecular Biology
Volume295
Issue number4
DOIs
StatePublished - Jan 28 2000

Fingerprint

Gerstmann-Straussler-Scheinker Disease
Transgenic Mice
Peptides
Prion Diseases
Mutant Proteins
Protein Isoforms
Central Nervous System
Injections
Proteins

Keywords

  • β-pleated sheet
  • Gerstmann-Straussler-Scheinker (GSS) disease
  • Prion protein synthetic peptide
  • PrP amyloid plaques
  • PrP mutation (P102L)

ASJC Scopus subject areas

  • Virology

Cite this

A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice. / Kaneko, Kiyotoshi; Ball, Haydn L.; Wille, Holger; Zhang, Hong; Groth, Darlene; Torchia, Marilyn; Tremblay, Patrick; Safar, Jiri; Prusiner, Stanley B.; DeArmond, Stephen J.; Baldwin, Michael A.; Cohen, Fred E.

In: Journal of Molecular Biology, Vol. 295, No. 4, 28.01.2000, p. 997-1007.

Research output: Contribution to journalArticle

Kaneko, K, Ball, HL, Wille, H, Zhang, H, Groth, D, Torchia, M, Tremblay, P, Safar, J, Prusiner, SB, DeArmond, SJ, Baldwin, MA & Cohen, FE 2000, 'A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice', Journal of Molecular Biology, vol. 295, no. 4, pp. 997-1007. https://doi.org/10.1006/jmbi.1999.3386
Kaneko, Kiyotoshi ; Ball, Haydn L. ; Wille, Holger ; Zhang, Hong ; Groth, Darlene ; Torchia, Marilyn ; Tremblay, Patrick ; Safar, Jiri ; Prusiner, Stanley B. ; DeArmond, Stephen J. ; Baldwin, Michael A. ; Cohen, Fred E. / A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice. In: Journal of Molecular Biology. 2000 ; Vol. 295, No. 4. pp. 997-1007.
@article{a470c689d34c40d7926de60d7253189e,
title = "A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice",
abstract = "The molecular basis of the infectious, inherited and sporadic forms of prion diseases is best explained by a conformationally dimorphic protein that can exist in distinct normal and disease-causing isoforms. We identified a 55-residue peptide of a mutant prion protein that can be refolded into at least two distinct conformations. When inoculated intracerebrally into the appropriate transgenic mouse host, 20 of 20 mice receiving the β-form of this peptide developed signs of central nervous system dysfunction at ~360 days, with neurohistologic changes that are pathognomonic of Gerstmann-Straussler-Scheinker disease. By contrast, eight of eight mice receiving a non-β-form of the peptide failed to develop any neuropathologic changes more than 600 days after the peptide injections. We conclude that a chemically synthesized peptide refolded into the appropriate conformation can accelerate or possibly initiate prion disease. (C) 2000 Academic Press.",
keywords = "β-pleated sheet, Gerstmann-Straussler-Scheinker (GSS) disease, Prion protein synthetic peptide, PrP amyloid plaques, PrP mutation (P102L)",
author = "Kiyotoshi Kaneko and Ball, {Haydn L.} and Holger Wille and Hong Zhang and Darlene Groth and Marilyn Torchia and Patrick Tremblay and Jiri Safar and Prusiner, {Stanley B.} and DeArmond, {Stephen J.} and Baldwin, {Michael A.} and Cohen, {Fred E.}",
year = "2000",
month = "1",
day = "28",
doi = "10.1006/jmbi.1999.3386",
language = "English (US)",
volume = "295",
pages = "997--1007",
journal = "Journal of Molecular Biology",
issn = "0022-2836",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - A synthetic peptide initiates Gerstmann-Straussler-Scheinker (GSS) disease in transgenic mice

AU - Kaneko, Kiyotoshi

AU - Ball, Haydn L.

AU - Wille, Holger

AU - Zhang, Hong

AU - Groth, Darlene

AU - Torchia, Marilyn

AU - Tremblay, Patrick

AU - Safar, Jiri

AU - Prusiner, Stanley B.

AU - DeArmond, Stephen J.

AU - Baldwin, Michael A.

AU - Cohen, Fred E.

PY - 2000/1/28

Y1 - 2000/1/28

N2 - The molecular basis of the infectious, inherited and sporadic forms of prion diseases is best explained by a conformationally dimorphic protein that can exist in distinct normal and disease-causing isoforms. We identified a 55-residue peptide of a mutant prion protein that can be refolded into at least two distinct conformations. When inoculated intracerebrally into the appropriate transgenic mouse host, 20 of 20 mice receiving the β-form of this peptide developed signs of central nervous system dysfunction at ~360 days, with neurohistologic changes that are pathognomonic of Gerstmann-Straussler-Scheinker disease. By contrast, eight of eight mice receiving a non-β-form of the peptide failed to develop any neuropathologic changes more than 600 days after the peptide injections. We conclude that a chemically synthesized peptide refolded into the appropriate conformation can accelerate or possibly initiate prion disease. (C) 2000 Academic Press.

AB - The molecular basis of the infectious, inherited and sporadic forms of prion diseases is best explained by a conformationally dimorphic protein that can exist in distinct normal and disease-causing isoforms. We identified a 55-residue peptide of a mutant prion protein that can be refolded into at least two distinct conformations. When inoculated intracerebrally into the appropriate transgenic mouse host, 20 of 20 mice receiving the β-form of this peptide developed signs of central nervous system dysfunction at ~360 days, with neurohistologic changes that are pathognomonic of Gerstmann-Straussler-Scheinker disease. By contrast, eight of eight mice receiving a non-β-form of the peptide failed to develop any neuropathologic changes more than 600 days after the peptide injections. We conclude that a chemically synthesized peptide refolded into the appropriate conformation can accelerate or possibly initiate prion disease. (C) 2000 Academic Press.

KW - β-pleated sheet

KW - Gerstmann-Straussler-Scheinker (GSS) disease

KW - Prion protein synthetic peptide

KW - PrP amyloid plaques

KW - PrP mutation (P102L)

UR - http://www.scopus.com/inward/record.url?scp=0034723133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034723133&partnerID=8YFLogxK

U2 - 10.1006/jmbi.1999.3386

DO - 10.1006/jmbi.1999.3386

M3 - Article

C2 - 10656806

AN - SCOPUS:0034723133

VL - 295

SP - 997

EP - 1007

JO - Journal of Molecular Biology

JF - Journal of Molecular Biology

SN - 0022-2836

IS - 4

ER -